9995
COM:REMEGEN
荣昌生物制药（烟台）股份有限公司
- Stock
Last Close
18.06
22/11 08:08
Market Cap
14.40B
Beta: -
Volume Today
2.35M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | 30.46M - | 48.73M 59.97% | 173.26M 255.58% | 401.49M 131.73% | 632.12M 57.44% | ||
average payables | 42.22M - | 65.17M 54.36% | 110.95M 70.25% | 190.48M 71.67% | 180.51M 5.23% | ||
average receivables | 518.20M - | ||||||
book value per share | -1.04 - | -0.48 53.44% | 8.81 1,916.17% | 7.07 19.72% | 9.39 32.87% | 6.37 32.21% | |
capex per share | -0.18 - | -0.14 22.11% | -1.18 764.21% | -1.27 7.50% | -1.43 12.83% | -1.58 10.57% | |
capex to depreciation | -3.70 - | -1.52 58.77% | -6.19 306.08% | -5.12 17.23% | -4.06 20.68% | -3.65 10.15% | |
capex to operating cash flow | 0.65 - | 0.23 64.73% | 0.73 215.86% | -2.34 421.46% | 0.60 125.60% | 0.57 5.34% | |
capex to revenue | -7.40 - | -0.43 - | -0.99 127.57% | -0.79 20.19% | |||
cash per share | 0.01 - | 0.07 581.50% | 6.78 9,292.82% | 3.60 46.87% | 3.90 8.30% | 1.38 64.71% | |
days of inventory on hand | 1.21K - | 1.52K - | 706.74 53.61% | 1.05K 48.86% | |||
days payables outstanding | 684.27 - | 865.50 - | 299.76 65.37% | 197.67 34.06% | |||
days sales outstanding | 141.70 - | ||||||
debt to assets | 0.01 - | 0.09 1,016.40% | 0.05 49.37% | 0.02 48.53% | 0.03 10.92% | 0.22 693.02% | |
debt to equity | -0.01 - | -0.28 3,011.86% | 0.05 119.52% | 0.03 45.78% | 0.03 11.12% | 0.35 954.95% | |
dividend yield | 0.00 - | ||||||
earnings yield | -0.01 - | -0.02 72.33% | -0.02 40.51% | 0.01 139.94% | -0.04 508.11% | -0.08 126.38% | |
enterprise value | 29.07B - | 29.81B 2.54% | 29.95B 0.45% | 29.28B 2.23% | 25.47B 13.00% | 18.77B 26.30% | |
enterprise value over ebitda | -139.30 - | -86.70 37.76% | -50.68 41.55% | 72.76 243.56% | -31.57 143.40% | -13.67 56.71% | |
ev to operating cash flow | -227.09 - | -105.44 53.57% | -45.37 56.97% | 111.05 344.79% | -20.16 118.15% | -12.49 38.02% | |
ev to sales | 2.57K - | 20.56 - | 33.18 61.35% | 17.33 47.75% | |||
free cash flow per share | -0.44 - | -0.73 64.32% | -2.80 284.29% | -0.73 74.04% | -3.81 425.43% | -4.36 14.47% | |
free cash flow yield | -0.01 - | -0.01 60.42% | -0.04 200.30% | -0.01 67.41% | -0.07 545.66% | -0.13 74.20% | |
graham net net | -2.11 - | -1.82 13.70% | 5.58 406.56% | 2.43 56.48% | 2.43 0.14% | -1.23 150.38% | |
graham number | 3.63 - | 3.29 9.34% | 18.79 471.45% | 9.50 49.46% | 19.95 110.07% | 20.03 0.42% | |
income quality | 0.47 - | 0.66 38.55% | 0.95 43.95% | 0.95 0.89% | 1.27 32.58% | 0.99 21.40% | |
intangibles to total assets | 0.02 - | 0.01 31.29% | 0.01 1.50% | 0.01 14.75% | 0.01 26.36% | 0.03 180.34% | |
interest coverage | -5.78 - | -8.83 52.86% | -22.88 159.08% | 52.96 331.53% | -146.97 377.49% | ||
interest debt per share | 0.09 - | 0.23 144.92% | 0.56 143.65% | 0.22 60.11% | 0.32 46.12% | 2.23 587.01% | |
inventory turnover | 0.30 - | 0.24 - | 0.52 115.55% | 0.35 32.82% | |||
invested capital | -0.01 - | -0.28 3,011.86% | 0.05 119.52% | 0.03 45.78% | 0.03 11.12% | 0.35 954.95% | |
market cap | 29.07B - | 29.78B 2.43% | 32.52B 9.19% | 30.93B 4.88% | 27.38B 11.50% | 18.31B 33.10% | |
net current asset value | -964.39M - | -783.71M 18.74% | 2.45B 413.16% | 1.59B 35.33% | 2.17B 36.80% | 137.96M 93.65% | |
net debt to ebitda | 0.00 - | -0.09 3,452.49% | 4.35 4,954.30% | -4.11 194.48% | 2.36 157.42% | -0.33 114.13% | |
net income per share | -0.56 - | -0.99 76.52% | -1.78 79.81% | 0.57 131.81% | -1.88 432.12% | -2.80 48.76% | |
operating cash flow per share | -0.27 - | -0.59 120.85% | -1.62 173.61% | 0.54 133.44% | -2.38 540.75% | -2.78 16.81% | |
payables turnover | 0.53 - | 0.42 - | 1.22 188.73% | 1.85 51.65% | |||
receivables turnover | 2.58 - | ||||||
research and ddevelopement to revenue | 19.12 - | 0.50 - | 1.28 156.18% | 1.21 5.70% | |||
return on tangible assets | -0.51 - | -0.70 35.31% | -0.18 74.32% | 0.07 137.68% | -0.17 348.67% | -0.28 67.79% | |
revenue per share | 0.02 - | 2.92 - | 1.45 50.42% | 2.01 38.54% | |||
roe | 0.54 - | 2.04 279.10% | -0.20 109.90% | 0.08 139.63% | -0.20 349.95% | -0.44 119.44% | |
roic | 0.47 - | 2.64 461.45% | -0.18 106.79% | 0.08 142.14% | -0.19 347.07% | -0.33 78.32% | |
sales general and administrative to revenue | 0.83 - | 0.15 - | 0.35 129.92% | 0.28 20.86% | |||
shareholders equity per share | -1.04 - | -0.48 53.44% | 8.81 1,916.17% | 7.07 19.72% | 9.39 32.87% | 6.37 32.21% | |
stock based compensation to revenue | 0.27 - | 0.01 - | 0.07 438.03% | 0.08 8.77% | |||
tangible asset value | -506.79M - | -239.65M 52.71% | 3.55B 1,581.07% | 3.39B 4.38% | 4.92B 45.09% | 3.29B 33.12% | |
tangible book value per share | -1.06 - | -0.50 52.71% | 8.70 1,835.84% | 6.96 19.93% | 9.29 33.41% | 6.10 34.31% | |
working capital | -932.05M - | -719.38M 22.82% | 2.55B 453.92% | 1.68B 33.88% | 2.32B 37.79% | 1.10B 52.55% |
All numbers in (except ratios and percentages)